Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer
Publication Type:Journal Article
Source:Indian Journal of Clinical Biochemistry, Volume 18, Number 1, p.46-51 (2003)
Keywords:article, CA 125 antigen, cancer recurrence, carcinoembryonic antigen, colorectal cancer, disease marker, disease severity, Histology, human, immunoassay, major clinical study, metastasis, ovary cancer, Prognosis, tissue polypeptide antigen, tumor marker
The study was designed to evaluate the significance of tissue polypeptide specific antigen (TPS) in patients with histologically proven ovarian and colorectal cancer following treatment along with CA125 (in ovarian cancer) and CEA (in colorectal cancer). Patients were grouped as follows: Group I: Patients with stable disease Group II: Patients with metastasis and relapse In patients with ovarian and colorectal cancer, the mean TPS levels were significantly higher in patients of group II compared to group I. The percentage of patients above cut-off levels for TPS were 17.4% in group I and 95.5% in group II. Similar results were observed with the mean levels of CA125. In colorectal cancer patients, the percentage of patients above cut-off levels for CEA and TPS were 70% and 30% in group I and 100% in group II for both the markers. Our observations indicate that TPS may be used as a common marker to indicate metastases in patients with ovarian and colorectal cancer.
cited By 0
Cite this Research Publication
Related Research Publications
- Organ specific tumor markers: What's new?
- Surgical treatment pattern and outcomes in epithelial ovarian cancer patients from a cancer institute in Kerala, India.
- WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis
- A clinicopathological correlation of acute leukaemias in relation to immunophenotyping and cytogenetics
- A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: A prospective non-randomized observational study